- Home
- Implementing Heart Failure Guidelines with Collaborative Care
Implementing Heart Failure Guidelines with Collaborative Care
- Heart Failure
Available Credit:
- Not accredited
Course Published On:
Course Expiry Date:
Overview
This satellite symposium, presented and recorded at ESC 2023 in Amsterdam, by Prof Carolyn Lam (National Heart Centre Singapore, SG), provides an excellent opportunity to learn about the latest guideline recommendations in HFpEF and how to implement them effectively in clinical practice.
The panel of experts, including Dr Gianluigi Savarese (Karolinska Institute, Stockholm, SE), Dr Stephen Greene (Duke University School of Medicine, North Carolina, US), Prof Mark Petrie (University of Glasgow, Glasgow, UK) and Carys Barton (Imperial College Healthcare NHS Trust, London, UK) provide valuable insights into the challenges and barriers faced while adopting new guideline-directed medical therapy for heart failure patients. Collaborative care is an essential aspect of heart failure therapy and this session emphasises the significance of cross-functional teams in managing this condition.
Support Statement
This satellite symposium is supported by an unrestricted educational grant from AstraZeneca who had no involvement in the content.
Target Audience
- Cardiologists
- Heart Failure Specialists
- Primary Care Physicians
- Nurses, Pharmacists, and other Allied Healthcare Professionals
Learning Objectives
Upon completion of this activity, participants will be able to:
- Appraise new updates in heart failure guideline-directed medical therapy (GDMT)
- Apply latest guideline recommendations to patient cases
- Describe barriers preventing early initiation of GDMT
- Identify the roles of nurses and other healthcare professionals to achieve optimal heart failure therapy
- Identify the importance of the nurse/cross-functional team
Module |
Title |
Duration |
Speakers |
|---|---|---|---|
| Session 1 | Introduction and Part 1: Addressing New Guidelines | 20 mins | Carolyn Lam Mark Petrie Gianluigi Savarese Stephen J Greene Carys Barton |
| Session 2 | Early / Rapid Initiation of GDMT | 30 mins | Carolyn Lam Mark Petrie Gianluigi Savarese Stephen J Greene Carys Barton |
| Session 3 | Audience Q&A | 10 mins | Carolyn Lam Mark Petrie Gianluigi Savarese Stephen J Greene Carys Barton |
Introduction and Part 1: Addressing New Guidelines
Duration: 20 mins
Speakers: Carolyn Lam Mark Petrie Gianluigi Savarese Stephen J Greene Carys Barton
Early / Rapid Initiation of GDMT
Duration: 30 mins
Speakers: Carolyn Lam Mark Petrie Gianluigi Savarese Stephen J Greene Carys Barton
Audience Q&A
Duration: 10 mins
Speakers: Carolyn Lam Mark Petrie Gianluigi Savarese Stephen J Greene Carys Barton
Related Courses
- 1.00
Published:
Learning objectives
- To differentiate ATTR phenotypes based on presenting signs and symptoms.
- To select appropriate tests to monitor symptomatic ATTR-cm from imaging, biomarker, functional and QoL assessments.
- To recall how to identify disease progression across ATTR-cm.
- To describe the different disease modifying treatments for ATTR including novel agents.
- Not accredited
Published:
Learning objectives
- Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
- Recognise barriers preventing the use of GDMT in current practice.
- Identify strategies needed to drive implementation of GDMT in clinical practice.
- Not accredited
Published:
Learning objectives
- Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
- Identify patients who would benefit from anti-hyperkalaemia medications
- Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
- Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
- Summarise current guideline recommendations on the use of potassium binding agents
- 1.00
Published:
Learning objectives
- Identify individuals likely to have HFpEF from initial presentation
- Refer suspected individuals for specialist assessment
- Initiate GDMT for HF as soon as patients are stable
- Initiate GDMT in HF regardless of EF and phenotype
- Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
- 1.00
Published:
Learning objectives
- Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
- Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
- Select appropriate imaging modalities to facilitate accurate risk stratification
- Stratify patients based on specific risk features and disease severity
- Choose suitable treatment modalities for patients based on specific disease features and severity
- 1.00
Published:
Learning objectives
- Review current GDMT in HFrEF and HFpEF
- Describe the relationship between initiation of GDMT and HF outcomes
- Prescribe GDMT according to current international recommendations
- Recall the elements of the Kansas City Cardiomyopathy Questionnaire
- Describe the clinical studies that support the use of functional and QoL measures in practice
- Initiate quality of life and functional improvement measures in routine practice
- Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
- Adopt shared decision-making with HF patients
- 1.00
Published:
Learning objectives
- Recall the utility of EF in heart failure treatment, patient selection and treatment response
- Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
- Incorporate quality of life measures for assessing therapeutic efficacy in HF
- Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
- 1.00
Published:
Learning objectives
- Recall the results of key trials in HFmrEF in different patients' sub-groups
- Describe how SGLT-2 inhibitors can be used across the range of LVEF
- Apply emerging diagnostic approaches for HFpEF and HFmrEF
- Implement best-practice strategies across the range of LVEF
- Not accredited
Published:
Learning objectives
- Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
- Recall current inertia rates amongst prescribers who manage heart failure
- Adopt effective treatment strategies for HFpEF patients early in the disease course
- Recall current guideline directed medical therapy options in HFpEF
- Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF
- 1.00
Published:
Learning objectives
- Recall the utility of EF in heart failure treatment, patient selection and treatment response
- Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
- Incorporate quality of life measures for assessing therapeutic efficacy in HF
- Recall outcomes from heart failure trials from recent congress and publications and their impact on practice